Original Research J Clin Psychiatry July 2026

Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials

JCP 2026;87(3):10.4088/JCP.26m16448

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2026;87(3):10.4088/JCP.26m16448 Clinical Summary Hostility and agitation in schizophrenia can quickly undermine daily functioning and escalate into aggressive behavior, making them high-stakes symptoms to manage. This analysis asks a practical question clinicians face every day: whether brexpiprazole can improve functioning even in patients whose illness includes hostility or agitation. FAQ Did brexpiprazole improve functioning in patients with schizophrenia who had hostility symptoms? 10 questions
Key Takeaways In the 6-week pooled analysis, functional improvement with brexpiprazole remained significant after removing the PSP disturbing/aggressive behavior domain, suggesting benefit was not solely an artifact of direct improvement in hostility-related behaviors. 6 takeaways Clinical Guide How can clinicians identify when a patient with schizophrenia meets this study's hostility or agitation symptom thresholds? 5 steps Clinical Guide How should clinicians monitor functioning, hostility, and agitation when following a patient with schizophrenia treated with brexpiprazole? 6 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe